These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34189639)

  • 1. Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.
    Xu H; Li Y; Paxton JW; Wu Z
    Pharm Res; 2021 Jul; 38(7):1209-1219. PubMed ID: 34189639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug.
    Xu H; Paxton JW; Wu Z
    Pharm Res; 2015 Jul; 32(7):2428-38. PubMed ID: 25663325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
    Tang M; Svirskis D; Leung E; Kanamala M; Wang H; Wu Z
    J Control Release; 2019 Jul; 305():89-100. PubMed ID: 31096017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells.
    Xu H; Paxton JW; Wu Z
    Pharm Res; 2016 Jul; 33(7):1628-37. PubMed ID: 26964546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual pH-sensitive liposomes with low pH-triggered sheddable PEG for enhanced tumor-targeted drug delivery.
    Kanamala M; Palmer BD; Jamieson SM; Wilson WR; Wu Z
    Nanomedicine (Lond); 2019 Aug; 14(15):1971-1989. PubMed ID: 31355712
    [No Abstract]   [Full Text] [Related]  

  • 6. Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
    Deodhar S; Dash AK; North EJ; Hulce M
    AAPS PharmSciTech; 2020 Aug; 21(6):231. PubMed ID: 32778980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation.
    Kanamala M; Palmer BD; Ghandehari H; Wilson WR; Wu Z
    Pharm Res; 2018 May; 35(8):154. PubMed ID: 29855807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
    Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery.
    Tang M; Lozano Hernandez L; Reginald-Opara JN; Svirskis D; Leung E; Wang H; Wu Z
    Int J Pharm; 2021 Jun; 602():120659. PubMed ID: 33933647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.
    Xu H; Paxton J; Lim J; Li Y; Zhang W; Duxfield L; Wu Z
    Pharm Res; 2014 Oct; 31(10):2583-92. PubMed ID: 24639234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.
    Shrestha P; Ghanwatkar Y; Mahto S; Pramanik N; Mahato RI
    ACS Appl Mater Interfaces; 2024 Jun; 16(23):29686-29698. PubMed ID: 38813771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells.
    Masetto F; Chegaev K; Gazzano E; Mullappilly N; Rolando B; Arpicco S; Fruttero R; Riganti C; Donadelli M
    Biochim Biophys Acta Mol Cell Res; 2020 Dec; 1867(12):118824. PubMed ID: 32828758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy for the treatment of pancreatic cancer through hyaluronic acid-decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study.
    Serri C; Quagliariello V; Iaffaioli RV; Fusco S; Botti G; Mayol L; Biondi M
    J Cell Physiol; 2019 Apr; 234(4):4959-4969. PubMed ID: 30334571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of pancreatic cancer by targeted delivery of gemcitabine via fucoidan-coated pH-sensitive liposomes.
    Zheng Z; Li M; Yang J; Zhou X; Chen Y; Silli EK; Tang J; Gong S; Yuan Y; Zong Y; Kong J; Chen P; Yu L; Luo S; Wang Y; Tan C
    Int J Biol Macromol; 2024 Oct; 277(Pt 3):134517. PubMed ID: 39111497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
    Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
    J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
    Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
    Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.